Oryzon Genomics (BME: ORY)

Last close As at 08/02/2025

EUR1.46

0.01 (0.41%)

Market capitalisation

EUR94m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Latest Insights

View More

Healthcare | edison tv

Oryzon Genomics – executive interview

Healthcare | Flash note

Oryzon Genomics — FDA aligns on Phase III BPD plans

testalize-me-0jE8ynV4mis-unsplash

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Analyst, Healthcare

Key Management

  • Carlos Buesa

    CEO

Update

Healthcare

Oryzon Genomics — Approaching a period of inflection

Flash note

Healthcare

Oryzon Genomics — Promising PORTICO interim results

Oryzon-Genomics_resized

Update

Healthcare

Oryzon Genomics — Catalysts on the horizon in FY23

Flash note

Healthcare

Oryzon Genomics — Progress in oncology and CNS in FY22

Flash note

Healthcare

Oryzon Genomics — Encouraging safety data in PORTICO

Flash note

Healthcare

Oryzon Genomics — Costs up but company remains well funded

testalize-me-0jE8ynV4mis-unsplash

Flash note

Healthcare

Oryzon Genomics — CRADA win to provide a halo effect

Flash note

Healthcare

Oryzon Genomics — FRIDA funding and orphan drug designation

edison tv

Healthcare

Oryzon– Edison Open House interview

testalize-me-0jE8ynV4mis-unsplash

Update

Healthcare

Oryzon Genomics — First vafidemstat efficacy data

Update

Healthcare

Oryzon Genomics — A year of data readouts

edison tv

Healthcare

Executive interview – Oryzon

Outlook

Healthcare

Oryzon Genomics — Awaiting for eventful 2019

Update

Healthcare

Oryzon Genomics — ORY-2001 and ORY-3001 next in focus

Outlook

Healthcare

Oryzon Genomics — Maturing epigenetics portfolio

edison tv

Healthcare

Executive Interview – Oryzon

Update

Healthcare

Oryzon Genomics — New data further back MS indication

testalize-me-0jE8ynV4mis-unsplash

Update

Healthcare

Oryzon Genomics — Update 9 December 2016

Update

Healthcare

Oryzon Genomics — Update 16 November 2016

research

Healthcare

Oryzon Genomics — Update 3 November 2016

Update

Healthcare

Oryzon Genomics — Update 8 August 2016

Update

Healthcare

Oryzon Genomics — Update 20 May 2016

testalize-me-0jE8ynV4mis-unsplash

Initiation

Healthcare

Oryzon Genomics — Update 9 March 2016

QuickView

Healthcare

Oryzon Genomics — Update 5 January 2016